Tag Archives: Market Access
PBAC Outcomes – November 2019
The November 2019 PBAC Meeting Outcomes were published recently With 61 outcomes in total, the Commercial Eyes Market Access team provides an overview of PBAC decision making for this meeting, compared to the past 5 years of outcomes. Of note, … Continue reading
Pharmac reverses controversial brand switch decision
Pharmac has been placed in the spotlight over their decision earlier in the year to fund only one brand of anti-epileptic medication, lamotrigine, instead of the previously funded three lamotrigine brands. Prior to the switch, Medsafe warned Pharmac that the … Continue reading
Commercial Eyes appoints Simon Higgins to head up new Commercialisation Services division
Commercial Eyes Pty. Ltd., one of Australia’s most successful health technology commercialisation companies, is pleased to announce the appointment of Simon Higgins to head up it’s new Commercialisation Services division. Simon joins Commercial Eyes with over 20 years’ experience in … Continue reading
PHARMAC issues a call for funding applications for medicines for rare disorders
Applications will be accepted until 5pm on the 5th of August 2019 and will be considered by the Rare Disorders Subcommittee at their meeting scheduled for the 24th of September 2019. Eligibility criteria: The medicine must have been approved … Continue reading
PBAC Meeting Outcomes – July 2018
The July 2018 PBAC Meeting Outcomes were published on 17th August 2018. With 64 outcomes in total, the Commercial Eyes Market Access team provides an overview of PBAC decision making, including additional analysis conducted on biosimilar and oncology submissions. … Continue reading
PBAC Special Meeting – August 2018
The August 2018 PBAC special meeting is scheduled for 17 August 2018 to consider options for listing PD-1 and PD-L1 checkpoint inhibitors for the treatment of multiple tumours (pan-tumour indications) on the PBS. Here, the Commercial Eyes Market Access team … Continue reading
The long road to PBS listing for Orkambi
Orkambi (lumacaftor and ivacaftor), a treatment for cystic fibrosis (CF), will go before the PBAC for a fourth time at the upcoming July 2018 PBAC meeting. So far, the road to reimbursement has been filled with multiple rejections, a strong … Continue reading
PBAC Meeting Agenda – July 2018
The July 2018 PBAC Meeting is scheduled from 4 to 6 Jul 2018. Here, the Commercial Eyes Market Access team provides an overview of the meeting agenda, including submissions relating to biosimilars lodged for this meeting. The Commercial … Continue reading
PBAC Meeting Outcomes – March 2018
The March 2018 PBAC Meeting Outcomes were published on 20th April 2018. With 71 outcomes in total, the Commercial Eyes Market Access team provides an overview of PBAC decision making, including an additional analysis conducted on oncology submissions which have … Continue reading
PBAC outcomes: a snapshot of 2017
The Commercial Eyes Market Access Team can help you navigate Australia and New Zealand’s sophisticated and mature systems of Health Technology Assessment. Contact us on (03) 9251 0777 to learn more about our PBAC Outcomes Database and let us … Continue reading
